angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Thus, metal chelates are relevant to the mobilization of metals in the soil, the uptake and the accumulation of metals into plants and microorganisms. Selective chelation of heavy metals is relevant to bioremediation (e.g., removal of 137Cs from radioactive waste).
Since the fall of the Eastern European Marxist–Leninist regimes, the Soviet Union and a variety of African Marxist–Leninist regimes in 1991, only a few Marxist–Leninist parties remained in power. This include China, Cuba, Laos, and Vietnam. Most Marxist–Leninist communist parties outside of these nations have fared relatively poorly in elections, although other parties have remained or became a relative strong force. In Russia, the Communist Party of the Russian Federation has remained a significant political force, winning the 1995 Russian legislative election, almost winning the 1996 Russian presidential election, amid allegations of United States foreign electoral intervention, and generally remaining the second most popular party. In Ukraine, the Communist Party of Ukraine has also exerted influence and governed the country after the 1994 Ukrainian parliamentary election and again after the 2006 Ukrainian parliamentary election. The 2014 Ukrainian parliamentary election following the Russo-Ukrainian War and the annexation of Crimea by the Russian Federation resulted in the loss of its 32 members and no parliamentary representation. In Europe, several Marxist–Leninist parties remain strong. In Cyprus, Dimitris Christofias of AKEL won the 2008 Cypriot presidential election. AKEL has consistently been the first and third most popular party, winning the 1970, 1981, 2001, and 2006 legislative elections.
Polyphenol oxidases are a family of di-copper metalloenzymes that include tyrosinase and catechol oxidase. In plants, both enzymes can catalyze the oxidation of ortho-diphenols substrates into their corresponding ortho-quinones. The key difference between the two related enzymes is that tyrosinase can catalyze the hydroxylation of monophenols to diphenols (monophenolase activity) as well as the oxidation of the o-diphenol to the o-quinone (diphenolase activity) whereas catechol oxidase only possesses diphenolase activity. When plant tissue is damaged, the chloroplast may rupture and release catechol oxidase into the plant cytoplasm, and vacuoles may also rupture, releasing stored catechol into the cytoplasm. The tissue damage also allows oxygen to penetrate into the cell. Thus, tissue damage facilitates the interaction of catechol oxidase with its substrate to produce o-benzoquinone, which can polymerize non-enzymatically to yield melanins that form an insoluble barrier for wound protection.
Sources: en.wikipedia.org
James Upton (1670 in Wilmslow–1749), an English clergyman, schoolmaster and literary editor. Samuel Finney (1719 in Wilmslow–1798), an English miniature painter. William Ewart Gladstone (1809–1898), politician, statesman and Prime Minister four separate times, lived at the Wilmslow Rectory between January and April 1828 to study under the supervision of Reverend John Turner James Tait (1863–1944 in Wilmslow), medieval historian, noted for his retiring, scholarly life in Wilmslow Sir Thomas Barnes (1888–1964), lawyer and HM Procurator General and Treasury Solicitor 1934–1953 Helen Tolson (1888–1955), suffragette, active in the Women's Social and Political Union Alan Turing (1912–1954 in Wilmslow), computer science pioneer and driving force behind the Bombe machine for cracking the German Enigma cypher, is perhaps Wilmslow's most notable resident; he died locally In 2004, a blue plaque was placed on his house in his honour Patrick George (1923 in Wilmslow–2016), an English painter who taught at the Slade School of Fine Art Roger Thatcher (1926–2010), a British statistician, spent his formative early years in Wilmslow Antony Grey (1927 in Wilmslow–2010), pioneer gay rights activist Ronald Brunskill (1929–2015), architectural historian Rod Davies (1930–2015), astronomer and cosmologist, president of the Royal Astronomical Society, and director of Jodrell Bank Observatory Peter Emerson Jones (born 1935), owner of the Emerson Group, a property business lives locally Richard Evans (born 1945 in Wilmslow), a graphic designer, photographer and illustrator Iqbal Ahmed (born 1956), the owner and CEO of the Seamark Group's Asian food business, based in Manchester, lives in Wilmslow John Harris (born 1969 in Wilmslow), a British journalist, writer and critic.
=== December === December 3 – Nidal Hasan is scheduled to be executed. If carried out, he would be the first sitting member of the United States Armed Forces to be executed since John A. Bennett was executed in 1961 for rape and attempted murder and the first person executed publicly in the U.S. since that of Roscoe Jackson in 1937.
Although an estimated 43,000 species of bacteria have been named, most of them have never been studied. In fact, just 10 bacterial species account for half of all publications, whereas nearly 75% of all named bacteria have no academic research devoted to them. The best-studied species, Escherichia coli, has more than 300,000 studies published on it, but many of these papers likely use it only as a cloning vehicle to study other species, without providing any insight into its own biology. 90% of scientific studies on bacteria focus on less than 1% of species, mostly pathogenic bacteria relevant to human health. While E. coli is probably the best-studied bacterium, a quarter of its 4000 genes are poorly studied or remain uncharacterized. Some bacteria with minimal genomes (< 600 genes, e.g. Mycoplasma) usually have a large fraction of their genes functionally characterized, given that most of them are essential and conserved in many other species.
If the predicted half-life falls into an experimentally accessible range, such isotopes have a chance to move from the list of stable nuclides to the radioactive category, once their activity is observed. For example, 209Bi and 180W were formerly classed as stable, but were found to be alpha-active in 2003. However, such nuclides do not change their status as primordial when they are found to be radioactive. Most stable isotopes on Earth are believed to have been formed in processes of nucleosynthesis, either in the Big Bang, or in generations of stars that preceded the formation of the Solar System. However, some stable isotopes also show abundance variations in the earth as a result of decay from long-lived radioactive nuclides. These decay-products are termed radiogenic isotopes, in order to distinguish them from the much larger group of 'non-radiogenic' isotopes.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.